VASOTEC

Compare VASOTEC  to:
Compare
Compare

Generic Name for VASOTEC

Enalapril maleate 2.5mg+, 5mg+, 10mg, 20mg; tabs; +scored.

Legal Classification:

Rx

Pharmacological Class for VASOTEC

ACE inhibitor.

Manufacturer of VASOTEC

Biovail Pharmaceuticals, Inc.

Indications for VASOTEC

Hypertension.

Adult dose for VASOTEC

If on diuretics or CrCl <30mL/min: suspend diuretic for 2–3 days, if possible: initially 2.5mg daily; max 40mg. Monitor closely for first 2 wks. Others: initially 5mg daily. Usual range: 10–40mg daily in 1–2 divided doses.

Children's dosing for VASOTEC

Not recommended.

Contraindications for VASOTEC

History of ACEI-associated or other angioedema. Pregnancy (Cat.D in 2nd and 3rd trimesters).

Precautions for VASOTEC

Renal impairment. Salt/volume depletion. CHF. Dialysis (esp. high-flux membrane). Renal artery stenosis. Surgery. Monitor for hyperkalemia in diabetics. Monitor WBCs in renal or collagen vascular disease. Discontinue if neutropenia, angioedema, or laryngeal edema occurs. Pregnancy (Cat.C in 1st trimester). Nursing mothers.

Interactions for VASOTEC

Hypotension with diuretics. Hyperkalemia with K+-sparing diuretics or K+ supplements. May increase lithium levels. May be antagonized by NSAIDS.

Adverse Reactions for VASOTEC

Cough, headache, dizziness, fatigue, diarrhea, rash, orthostatic hypotension, asthenia, hyperkalemia, renal impairment, nausea.

How is VASOTEC supplied?

Tabs—90, 100, 1000

Related Disease:

Hypertension

Related Resources

FDA warns of reduced Plavix efficacy in poor metabolizers

March 15, 2010

The FDA has notified healthcare professionals and patients that a Boxed Warning has been added to the Plavix (clopidogrel tablets, from Bristol-Myers Squibb and Sanofi) Prescribing Information to include information about reduced Plavix efficacy in patients who are poor metabolizers of Plavix.

Benicar gains expanded indication for treatment of hypertension in children

February 11, 2010

The FDA has approved Benicar (olmesartan medoxomil tablets, from Daiichi Sankyo) for the treatment of hypertension in children and adolescents 6-16 years of age.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Cleviprex injection recalled due to presence of particulate matter

December 17, 2009

The FDA and The Medicines Company have notified healthcare professionals of a voluntary nationwide recall of 11 lots of Cleviprex (clevidipine butyrate) injection emulsion due to the presence of visible particulate matter observed in some vials.

Clonidine ER Suspension and Clonidine ER Tablets approved

December 07, 2009

Tris Pharma announced that the FDA has approved Clonidine ER suspension and Clonidine ER tablets, both of which utilize its proprietary OralXR+ platform technology to allow for once daily dosing.